- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04095221
A Study of the Drugs Prexasertib, Irinotecan, and Temozolomide in People With Desmoplastic Small Round Cell Tumor and Rhabdomyosarcoma
A Phase I/II Dose Escalation/Dose Expansion Study of Prexasertib in Combination With Irinotecan in Patients With Relapsed or RefractoryDesmoplastic Small Round Cell Tumor and Rhabdomyosarcoma
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10065
- Memorial Sloan Kettering Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Consent/Assent: all patients and/or their parents or legally authorized representatives must sign written informed consent; assent, when appropriate, will be obtained according to institutional guidelines
- Age: patients must be ≥12 months of age at the time of study enrollment
- Diagnosis: patients must have histologically documented locally advanced or metastatic desmoplastic small round cell tumor or rhabdomyosarcoma (confirmed at MSK)
- Therapeutic options: patient's current disease state must be one which has failed standard therapy and for which there is no known curative therapy
- Disease Status: patients must have measurable disease based on RECIST 1.1
- Performance level: Karnofsky ≥ 50% for patients > 16 years of age and Lansky ≥ 50 for patients ≤ 16 years of age
Prior Therapy: patients may have had any number of prior therapies, but must have recovered from the acute toxic effects of all prior anti-cancer therapy (other than alopecia) as described below and must meet the following minimum duration from prior anti-cancer directed therapy prior to enrollment
°patients who have previously received irinotecan and/or temozolomide will be allowed
- 21 days must have elapsed after the last dose of cytotoxic or myelosuppressive chemotherapy
- 7 days must have elapsed after the last dose of anti-cancer agents not known to be myelosuppressive
- 14 days must have elapsed after radiation therapy, and toxicity related to prior radiation therapy must be recovered to grade ≤ 1
- 21 days must have elapsed after the last dose of antibody therapy, and toxicity related to prior antibody therapy must be recovered to grade ≤ 1
Organ Function Requirements: Adequate bone marrow function defined as:
- absolute neutrophil count (ANC) ≥ 1500/mm^3
- platelet count ≥ 100,000/ mm^3
- hemoglobin ≥ 8 g/dl
Adequate renal function defined as:
- Creatinine clearance or radioisotope glomerular filtration rate ≥ 70 mL/min/1.73m2 OR
- Serum creatinine based on age/gender derived from the Schwartz formula for estimating GFR53
Adequate liver function defined as:
- Bilirubin (sum of conjugated + unconjugated) ≤ 1.5 x upper limit of normal for age
- AST or ALT ≤ 5 x upper limit of normal for patients with liver metastases
- Serum albumin ≥ 2.5 g/dl
Adequate cardiac function defined as:
- echocardiogram with left ventricular ejection fraction (LVEF) >45%
- QTc < 470 ms on screening 12 lead electrocardiogram
Pregnancy/Contraception
- post-menarchal females must have a negative urine or serum pregnancy test at screening and ≤ 24 hours prior to study treatment
- males or females of reproductive potential must be willing to use a barrier method of contraception throughout the course of the study and for 6 months after participation
Exclusion Criteria:
- Patients for whom the investigator deems that irinotecan and temozolomide are not appropriate are not eligible.
- Patients who have an uncontrolled infection are not eligible.
- Patients who are pregnant or breast feeding are not eligible.
- Patients who have a history of Torsades de Pointes, carry a diagnosis of congestive heart failure, or have a family history of prolonged QT syndrome are not eligible.
- Patients who, in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study are not eligible.
- Patients with known hypersensitivity to irinotecan or its excipients are not eligible.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Prexasertib and Irinotecan
Patients will have extent of disease scans following every 2 cycles (every 6 weeks on dose levels 0-3, and every 8 weeks on dose level -1 (if required).
Patients will be allowed to continue therapy as long as they do not experience dose-limiting toxicities or progression of disease.
|
DOSE LEVELS FOR PATIENTS > 21 YEARS OF AGE, Dose Level -1, prexasertib 105 mg/ m2 once every 14 days in 28 day cycles Dose Level 0, 60 mg/m2 prexasertib once every 21 days Dose Level 1, (STARTING) 80 mg/m2 prexasertib once every 21 days Dose Level 2, 105 mg/m2 prexasertib once every 21 days Dose Level 3, 105 mg/m2 prexasertib once every 21 days DOSE LEVELS FOR PATIENTS ≤ 21 YEARS OF AGE Dose Level -1, prexasertib 150 mg/ m2 once every 14 days in 28 day cycles, Dose Level 0, 60 mg/m2 prexasertib once every 21 days, Dose Level 1, (STARTING) 80 mg/m2 prexasertib once every 21 days, Dose Level 2, 150 mg/m2 prexasertib once every 21 days, Dose Level 3, 150 mg/m2 prexasertib once every 21 days
15 mg/m2 IV daily x 10 days in 21 day cycles
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
recommended phase II does of Prexasertib
Time Frame: 1 year
|
The RP2D is defined as the highest dose level associated with not more than 1 DLT out of 6 patients.
A total of 5 dose levels are planned, including 2 back up levels.
The DLT's will be graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.
The dose escalation will follow a 3+3 design.
|
1 year
|
response
Time Frame: 2 years
|
will be evaluated in this study using the criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) guideline, version 1.1 (Primary response criteria)54.
Changes in the largest diameter (unidimensional measurement) of the tumor lesions and the shortest diameter in the case of malignant lymph nodes are used in the RECIST criteria.
|
2 years
|
Collaborators and Investigators
Investigators
- Principal Investigator: Emily Slotkin, MD, Memorial Sloan Kettering Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms, Connective and Soft Tissue
- Neoplasms by Histologic Type
- Neoplasms
- Sarcoma
- Neoplasms, Muscle Tissue
- Myosarcoma
- Rhabdomyosarcoma
- Desmoplastic Small Round Cell Tumor
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Topoisomerase Inhibitors
- Protein Kinase Inhibitors
- Topoisomerase I Inhibitors
- Irinotecan
- Prexasertib
Other Study ID Numbers
- 19-120
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rhabdomyosarcoma
-
Children's Oncology GroupNational Cancer Institute (NCI)RecruitingAlveolar Rhabdomyosarcoma | Embryonal Rhabdomyosarcoma | Botryoid-Type Embryonal Rhabdomyosarcoma | Spindle Cell Rhabdomyosarcoma | Spindle Cell/Sclerosing Rhabdomyosarcoma | Metastatic Embryonal Rhabdomyosarcoma | Metastatic Rhabdomyosarcoma | Solid Alveolar RhabdomyosarcomaUnited States, Canada, Australia, Puerto Rico, Saudi Arabia
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Childhood Rhabdomyosarcoma | Previously Treated Childhood Rhabdomyosarcoma | Alveolar Childhood Rhabdomyosarcoma | Embryonal Childhood Rhabdomyosarcoma | Previously Untreated Childhood RhabdomyosarcomaUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Childhood Rhabdomyosarcoma | Previously Treated Childhood Rhabdomyosarcoma | Alveolar Childhood Rhabdomyosarcoma | Embryonal Childhood Rhabdomyosarcoma | Embryonal-botryoid Childhood RhabdomyosarcomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingRhabdomyosarcoma | Alveolar Rhabdomyosarcoma | Embryonal Rhabdomyosarcoma | Botryoid-Type Embryonal Rhabdomyosarcoma | Sclerosing Rhabdomyosarcoma | Spindle Cell RhabdomyosarcomaUnited States, Canada, Puerto Rico, Australia, New Zealand
-
National Cancer Institute (NCI)CompletedStage IV Adult Soft Tissue Sarcoma | Adult Rhabdomyosarcoma | Metastatic Childhood Soft Tissue Sarcoma | Childhood Alveolar Rhabdomyosarcoma | Childhood Embryonal Rhabdomyosarcoma | Untreated Childhood RhabdomyosarcomaUnited States, Canada, Australia, New Zealand
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Rhabdomyosarcoma | Alveolar Childhood Rhabdomyosarcoma | Embryonal Childhood RhabdomyosarcomaUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Childhood Rhabdomyosarcoma | Recurrent Adult Soft Tissue Sarcoma | Previously Treated Childhood Rhabdomyosarcoma | Adult Rhabdomyosarcoma | Childhood Alveolar Rhabdomyosarcoma | Childhood Pleomorphic Rhabdomyosarcoma | Childhood Rhabdomyosarcoma With Mixed Embryonal and Alveolar FeaturesUnited States, Canada, Australia, New Zealand
-
Children's Oncology GroupNational Cancer Institute (NCI)RecruitingEmbryonal Rhabdomyosarcoma | Fusion-Negative Alveolar Rhabdomyosarcoma | Spindle Cell/Sclerosing RhabdomyosarcomaUnited States, Australia, Canada, New Zealand
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedAdult Rhabdomyosarcoma | Embryonal Childhood Rhabdomyosarcoma | Embryonal-botryoid Childhood Rhabdomyosarcoma | Previously Untreated Childhood RhabdomyosarcomaUnited States, Canada, Australia, New Zealand, Puerto Rico, Switzerland
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Childhood Rhabdomyosarcoma | Previously Treated Childhood Rhabdomyosarcoma | Alveolar Childhood Rhabdomyosarcoma | Embryonal Childhood Rhabdomyosarcoma | Previously Untreated Childhood RhabdomyosarcomaUnited States
Clinical Trials on Prexasertib
-
Eli Lilly and CompanyCompletedAdvanced CancerUnited Kingdom
-
Dana-Farber Cancer InstituteEli Lilly and CompanyCompleted
-
Eli Lilly and CompanyCompletedOvarian CancerUnited States, Israel, Spain, Korea, Republic of, Australia, Belgium, United Kingdom, Italy
-
Eli Lilly and CompanyCompletedSmall Cell Lung CancerSpain, United States, Germany, Ukraine, France, Greece, Turkey, Netherlands, United Kingdom, Korea, Republic of
-
Eli Lilly and CompanyCompletedCarcinoma, Non-Small-Cell Lung | Advanced Cancer | Anal Squamous Cell Carcinoma | Squamous Cell Carcinoma | Carcinoma, Squamous Cell of Head and Neck | Lung Squamous Cell Carcinoma Stage IVUnited States
-
Dana-Farber Cancer InstituteCompletedAdvanced CancersUnited States
-
National Cancer Institute (NCI)TerminatedBreast Cancer | Ovarian Cancer | Prostate CancerUnited States
-
Eli Lilly and CompanyCompleted
-
Eli Lilly and CompanyCompletedColorectal Cancer | Metastatic Cancer | Non-small Cell Lung Cancer | Advanced CancerUnited States, Germany
-
Baylor Research InstituteEli Lilly and CompanyCompletedTriple Negative Breast CancerUnited States